AR‐42 is also a pan‐HDAC inhibitor and has been investigated in phase I stage for multiple myeloma, T‐ and B‐cell lymphomas, AML, and solid tumors (NCT01129193 and NCT01798901).572, 573. The gene discussed is HDAC9; the disease is acute myeloid leukemia.